CONTACT
JPEN

GROUP LEADER

TERUMITSU HASEBE

M.D., Ph.D. (Dr. Eng.)

Professor and Chairman, Department of Radiology (Current)
Director, Interventional Radiology, Tokai University Hachioji Hospital (Current)
Director, Vascular and Interventional Center, Tokai University School of Medicine (Current)
Visiting Professor, Keio University Hosipital Clinical and Translational Research Center (Current)
Leader, Hasebe Research Group

Visiting Professor, Prof. Elazer R.  Edelman laboratory, 
Institute for Medical Engineering and Science (IMES), the Massachusetts Institute of Technology (MIT), Harvard-MIT Biomedical Engineering Center

Japan Agency for Medical Research and Development (AMED)
  • Principle investigator of AMED’s SENTAN Program (Medical Reseach and Development Programs Forcused on Technology Transfer: Development of Advanced Measurement and Analysis Systems)
  • Principle investigator of AMED’s Project of Translational and Clinical Research Core Centers
Specialty
  • Diagnostic Radiology: CT, MRI, Gastrointestinal, Echo, PET, Nuclear Medicine
  • Endovascular treatment, Interventional Radiology (including non-vascular lung and bile duct)
  • Materials engineering, mechanical engineering, nanotechnology
Activity

In clinical medicine, Terumitsu Hasebe, M.D., Ph.D. is a specialist in diagnostic radiology and sub-imaging (interventional radiology (IR) and catheterization) with over 25 years of clinical experience. He has a Ph.D. in both medicine and engineering from Keio University School of Medicine and Keio University School of Science and Technology. He is a rare expert in Japan who can apply the results of his research in medicine and engineering from a clinical perspective to develop devices that solve unmet clinical needs. In 2010, he received the 16th Sakaki Encouragement Award from the Japan Society for the Promotion of Science (JSPS) for “Development of a new stent and detailed analysis using physical analysis methods. In addition, he has received 29 awards for excellence and grand prizes at academic conferences and symposiums in Japan and abroad, and has many patents.
He has served as an expert committee member and an advisor of the Pharmaceuticals and Medical Devices Agency (PMDA) for many years, and is well versed in pharmaceutical affairs. He has also served as a chairman of the Japanese Society of Interventional Radiology, where he has coordinated with PMDA, the Ministry of Health, Labor and Welfare, and other academic societies, as well as a member of the committee to formulate guidelines for proper use. In a very recent case related to COVID-19, he served as a member of the PMDA’s expert committee for early approval of an AI (artificial intelligence)-powered diagnostic imaging program that suggested the possibility of COVID-19 pneumonia.

Since 2000, he has been running a medical-engineering collaboration team consisting of Tokai University School of Medicine and Keio University Faculty of Science and Technology, and has been actively developing medical devices such as anti-thrombogenic medical devices. As a sub-leader, he developed and conducted pre-clinical studies on “Research and development for the production of cerebrovascular thrombectomy microsystems”, which was adopted as a large-scale project by the Ministry of Economy, Trade and Industry in 2013. Currently, this product is already being used in clinical settings after undergoing clinical trials in Japan, and is a device that is widely used and covered by insurance (Tron Fx, Biomedical Solutions; marketed by Terumo Corporation). In addition, his research on anti-thrombogenic nanocoatings has contributed to the development of a coronary drug-eluting stent made in Europe. Currently, he is a project leader of the Development of Advanced Measurement and Analysis Systems (development of a long-term patency system for small-diameter atherosclerotic lesions of the below-the-knee (BTK) artery) and the Strategic Promotion Program for Bridging Research (development of a high-definition MR lymph node). In this process, he has also played an important role in the establishment of many medical device venture companies in Japan.